Navigation Links
Cantel Medical Acquires Sterilator Company, Inc.
Date:1/8/2014

LITTLE FALLS, N.J., Jan. 8, 2014 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN), through its Crosstex subsidiary, has further expanded its sterility assurance monitoring business with the acquisition of Sterilator Company, Inc.  Based in Cuba, NY, Sterilator Company is a high-quality manufacturer of biological indicators and supplies for sterility assurance products, which are used to accurately monitor the effectiveness of sterilization processes.  Sterilator serves both the medical and industrial markets, and has been a long-time supplier of self-contained biological indicators, dual species spore strips and culture media to our dental and hospital healthcare disposable business. 

Gary Steinberg, President and CEO of Crosstex said, "This acquisition allows us to add one of our key long-standing suppliers of biological indicators to our portfolio, providing a strategic benefit to our overall sterility assurance monitoring business.  I am also pleased that we will retain Sterilator's current leadership, who will serve an integral role in new product development and R&D initiatives in sterility assurance."

Andrew Krakauer, President and CEO of Cantel Medical added, "This acquisition further enhances our capabilities as a leading provider of sterility assurance monitoring products to the medical industry.  Furthermore, this addition strengthens our product development capabilities, enabling Cantel to continue providing the best infection prevention and control products and solutions to our customers."

About Cantel Medical Corp.
Cantel Medical is a leading global company dedicated to delivering innovative infection prevention and control products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives.  Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates, hollow fiber membrane filtration and separation products, and specialty packaging for infectious and biological specimens. Additionally, we provide technical service for our products.  For further information, visit the Cantel website at www.cantelmedical.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.


'/>"/>
SOURCE Cantel Medical Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cantel Medical Reports 19% Sales Growth And EPS Of $0.27 vs. $0.23 For The First Quarter Ended October 31, 2013
2. Cantel Medical To Present At The 25th Annual Piper Jaffray Healthcare Conference
3. Cantel Medical Acquires Jet Prep Ltd.
4. Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2013 Ended July 31, 2013
5. Record Date Of Cantel Medicals Regular Semiannual Dividend Changed To July 23, 2013
6. Cantel Medical Reports EPS of $0.33 vs. $0.30 on 8% Sales Increase for Third Quarter Ended April 30, 2013
7. Cantel Medical Corp. To Hold Conference Call To Discuss Results for Its Third Quarter Ended April 30, 2013
8. Cantel Medical To Present At The Bank Of America Merrill Lynch Health Care Conference
9. Cantel Medical To Present At Needham 12th Annual Healthcare Conference
10. Cantel Medicals Mar Cor Purification Subsidiary Acquires Hemodialysis Water Business from Siemens Water Technologies Business Unit
11. Cantel Medical Reports EPS of $0.38 vs. $0.27 on 9% Sales Increase for Second Quarter Ended January 31, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... -- Research and Markets has announced the addition of the ... Forecast" report to their offering. ... Proton Therapy Market in Italy will ... There are currently three proton therapy centers in Italy ... Italy , the first patients were treated with proton ...
(Date:3/29/2017)... and Markets has announced the addition of the "South Korean Proton ... report to their offering. ... The South Korean Proton Therapy Market is expected to almost triple ... Therapy Market for South Korea was valued at ... plays an important role in delivering comprehensive cancer care to children and ...
(Date:3/29/2017)... HUNTINGTON BEACH, Calif. , March 29, 2017 ... treatment have recognized remote monitoring devices like  Soberlink ... monitoring.   The consensus paper, published in early ... "feasible, practical and valuable in managing patient recovery." ... published in the Journal of Addiction Medicine, detail ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its Serve, Learn, ... school and college students who have participated in the program every summer. The ... now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest ... in two southeastern states. Ingredients in HeartBoost, an over the counter heart healthy ...
(Date:3/29/2017)... ... , ... Dr. Angela Cotey, a noted general dentist in Mt. Horeb, is ... or without a referral. Dr. Cotey knows that interceptive orthodontics in Mt. ... patients receive early treatment, they may achieve straight teeth with less treatment in their ...
(Date:3/29/2017)... ... , ... Curio Wellness , a premium medical cannabis brand and trusted ... management team with prominent executives from both inside and outside the cannabis industry. ... Ted Dumbauld , who has more than twenty years of business leadership and investment ...
(Date:3/29/2017)... ... 29, 2017 , ... Immunotherapy has emerged as one of the most promising ... to be the next revolution in our fight against this complex disease. One of ... immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single ...
Breaking Medicine News(10 mins):